Report Shows Byetta, Januvia and Other Incretin Mimetic Drugs for Type 2 Diabetes Linked to Increased Risk of Pancreatic Cancer, Parker Waichman LLP Warns

April 19, 2013

According to the Institute for Safe Medication Practices´ most recent QuarterWatch report, incretin mimetic drugs such as Byetta, Januvia and Victoza may be 25 times more likely to be linked to pancreatic cancer. This class of medications is currently under investigation by the U.S. Food and Drug Administration (FDA) after researchers found evidence of precancerous cell changes in pancreatic tissue samples from patients who took the Type 2 diabetes drugs.

New York, New York (PRWEB) April 19, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs and devices, is recounting the risks of medications such as Byetta (exenatide), Januvia (sitagliptin) and Victoza (liraglutide) in light of information released by the Institute for Safe Medication Practices´ (ISMP) most recent QuarterWatch report*. According to the report, glucagon-like peptide-1 (GLP-1) agents such as Byetta, Victoza, Januvia, Onglyza (saxagliptin) and Tradjenta (linagliptin) are 25 times more likely to be linked to pancreatic cancer.

The report, which was issued on April 18th, used information from the U.S. Food and Drug Administration (FDA)´s adverse event report database to analyze a year´s worth of reports related to the Type 2 diabetes drugs, also known as incretin mimetics. ISMP found that there were 105 cases of pancreatic cancer linked to these medications, compared to another class of diabetes drugs; 71 of those cases were associated with Byetta. The watchdog group also found that injectable incretin mimetics were 28 times more likely to be associated with pancreatitis, or inflammation of the pancreas, while the oral agents were 20 times more likely to lead to the condition. “These data and other recent studies establish the need to reassess the safety of this class of drugs,” the ISMP report stated.

“The ISMP report confirms previous research showing that these diabetes drugs may increase the likelihood of developing pancreatitis and pancreatic cancer,” says William J. Dubanevich, an attorney at Parker Waichman LLP. “We remind consumers who take these medications to be aware of these risks.” The national personal injury law firm offers free legal advice to patients who developed pancreatitis or pancreatic cancer after taking incretin mimetics such as Januvia and Byetta.

Last month, the FDA** announced that it was investigating incretin mimetic drugs after researchers found evidence of pancreatitis and pre-cancerous cell changes known as pancreatic duct metaplasia. Several weeks later, the European Medicines Agency launched a similar probe. According to the FDA, incretin mimetic drugs include: exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto.



Parker Waichman LLP continues to offer free legal consultations to victims who suffered alleged injuries from Januvia, Byetta or Victoza, including pancreatitis, pancreatic cancer and thyroid cancer. If you or a loved one were diagnosed with pancreatitis, pancreatic cancer or thyroid after taking Januvia, Byetta or Victoza, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).


Parker Waichman LLP

Gary Falkowitz, Managing Attorney

(800) LAW-INFO

(800) 529-4636


For the original version on PRWeb visit: http://www.prweb.com/releases/prwebByetta-Januvia-cancer/04/prweb10653663.htm

Source: prweb

comments powered by Disqus